Cara Therapeutics, Inc.
Cara Therapeutics, Inc. Fundamental Analysis
Cara Therapeutics, Inc. (CARA) shows weak financial fundamentals with a PE ratio of -35.77, profit margin of -3.47%, and ROE of -1.16%. The company generates $0.0B in annual revenue with weak year-over-year growth of -65.96%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of -412.2/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze CARA's fundamental strength across five key dimensions:
Efficiency Score
WeakCARA struggles to generate sufficient returns from assets.
Valuation Score
ExcellentCARA trades at attractive valuation levels.
Growth Score
ModerateCARA shows steady but slowing expansion.
Financial Health Score
ExcellentCARA maintains a strong and stable balance sheet.
Profitability Score
WeakCARA struggles to sustain strong margins.
Key Financial Metrics
Is CARA Expensive or Cheap?
P/E Ratio
CARA trades at -35.77 times earnings. This suggests potential undervaluation.
PEG Ratio
When adjusting for growth, CARA's PEG of 0.27 indicates potential undervaluation.
Price to Book
The market values Cara Therapeutics, Inc. at 17.90 times its book value. This suggests the stock is fully valued or overvalued on an asset basis.
EV/EBITDA
Enterprise value stands at -1.48 times EBITDA. This is generally considered low.
How Well Does CARA Make Money?
Net Profit Margin
For every $100 in sales, Cara Therapeutics, Inc. keeps $-3.47 as profit after all expenses.
Operating Margin
Core operations generate -5.03 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $-1.16 in profit for every $100 of shareholder equity.
ROA
Cara Therapeutics, Inc. generates $-35.74 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Cara Therapeutics, Inc. generates limited operating cash flow of $-355.35K, signaling weaker underlying cash strength.
Free Cash Flow
Cara Therapeutics, Inc. generates weak or negative free cash flow of $-355.35K, restricting financial flexibility.
FCF Per Share
Each share generates $-0.23 in free cash annually.
FCF Yield
CARA converts -2.69% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
-35.77
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.27
vs 25 benchmark
P/B Ratio
Price to book value ratio
17.90
vs 25 benchmark
P/S Ratio
Price to sales ratio
2.02
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.008
vs 25 benchmark
Current Ratio
Current assets to current liabilities
3.48
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
-1.16
vs 25 benchmark
ROA
Return on assets percentage
-0.36
vs 25 benchmark
ROCE
Return on capital employed
-0.72
vs 25 benchmark
How CARA Stacks Against Its Sector Peers
| Metric | CARA Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | -35.77 | 29.43 | Better (Cheaper) |
| ROE | -115.90% | 800.00% | Weak |
| Net Margin | -346.55% | -20145.00% (disorted) | Weak |
| Debt/Equity | 0.01 | 0.30 | Strong (Low Leverage) |
| Current Ratio | 3.48 | 4.64 | Strong Liquidity |
| ROA | -35.74% | -17936.00% (disorted) | Weak |
CARA outperforms its industry in 3 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Cara Therapeutics, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
-99.66%
Industry Style: Defensive, Growth, Innovation
DecliningEPS CAGR
99.38%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
99.48%
Industry Style: Defensive, Growth, Innovation
High Growth